582 related articles for article (PubMed ID: 12097384)
21. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
[TBL] [Abstract][Full Text] [Related]
22. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
[TBL] [Abstract][Full Text] [Related]
23. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand.
Chou AH; Tsai HF; Lin LL; Hsieh SL; Hsu PI; Hsu PN
J Immunol; 2001 Aug; 167(3):1347-52. PubMed ID: 11466352
[TBL] [Abstract][Full Text] [Related]
24. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
Thomas WD; Hersey P
J Immunol; 1998 Sep; 161(5):2195-200. PubMed ID: 9725211
[TBL] [Abstract][Full Text] [Related]
25. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.
Nieda M; Nicol A; Koezuka Y; Kikuchi A; Lapteva N; Tanaka Y; Tokunaga K; Suzuki K; Kayagaki N; Yagita H; Hirai H; Juji T
Blood; 2001 Apr; 97(7):2067-74. PubMed ID: 11264173
[TBL] [Abstract][Full Text] [Related]
26. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
27. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M
J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394
[TBL] [Abstract][Full Text] [Related]
28. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
29. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages.
Kaplan MJ; Ray D; Mo RR; Yung RL; Richardson BC
J Immunol; 2000 Mar; 164(6):2897-904. PubMed ID: 10706675
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.
Franciszkiewicz K; Le Floc'h A; Jalil A; Vigant F; Robert T; Vergnon I; Mackiewicz A; Benihoud K; Validire P; Chouaib S; Combadière C; Mami-Chouaib F
Cancer Res; 2009 Aug; 69(15):6249-55. PubMed ID: 19638592
[TBL] [Abstract][Full Text] [Related]
31. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
33. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines.
Liu Q; El-Deiry WS; Gazitt Y
Exp Hematol; 2001 Aug; 29(8):962-70. PubMed ID: 11495702
[TBL] [Abstract][Full Text] [Related]
34. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma.
Shimizu Y; Weidmann E; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Res; 1991 Nov; 51(22):6153-62. PubMed ID: 1718596
[TBL] [Abstract][Full Text] [Related]
35. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
36. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages.
Halaas O; Vik R; Ashkenazi A; Espevik T
Scand J Immunol; 2000 Mar; 51(3):244-50. PubMed ID: 10736093
[TBL] [Abstract][Full Text] [Related]
37. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
Maccalli C; Mortarini R; Parmiani G; Anichini A
Int J Cancer; 1994 Apr; 57(1):56-62. PubMed ID: 7908659
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
39. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.
Gong B; Almasan A
Cancer Res; 2000 Oct; 60(20):5754-60. PubMed ID: 11059770
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
